FEATURES OF THE IMMUNOLOGICAL PROFILE IN CHILDREN WITH JUVENILE ARTHRITIS OF SYSTEMIC ONSET DEPENDING ON DISEASE ACTIVITY

FULL TEXT:

Abstract

Relevance. Systemic juvenile idiopathic arthritis (sJIA) is a distinct autoinflammatory subtype of juvenile arthritis, characterized by pronounced systemic inflammation and extra-articular manifestations such as fever, rash, and hepatosplenomegaly. The disease is associated with dysregulated production of proinflammatory cytokines (IL-1β, IL-6, IL-18), which determine its severity and increase the risk of complications. Conventional inflammatory markers, such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), are often insufficiently specific for accurate assessment of disease activity. Therefore, studying cytokine profiles and identifying reliable immunological biomarkers is particularly relevant for timely diagnosis, objective evaluation of disease activity, and optimization of individualized treatment strategies in children with sJIA, ultimately contributing to improved clinical outcomes and better prognosis. Objective. To study the characteristics of the course of juvenile arthritis depending on disease activity in patients with systemic-onset juvenile idiopathic arthritis (sJIA). Materials and Methods. A prospective cohort study including 74 children with juvenile arthritis (44 of them with sJIA) was conducted from 2021 to 2023. The diagnosis was established according to the International League of Associations for Rheumatology (ILAR) criteria (2001). Immunological assessments included measurement of proinflammatory cytokines (IL-1, IL-6, IL-18, TNF-α) using the RANDOX biochip technology, as well as autoimmune markers (S-100, serum ferritin) by enzyme-linked immunosorbent assay (ELISA) on a Multiskan FS, conducted in the clinical laboratory of RSSPMCP. The level of disease activity was assessed using the Juvenile Arthritis Disease Activity Score 27 (JADAS27). Statistical analysis was performed using StatPlus v8.0.3 and Microsoft Excel; correlations were assessed with Spearman’s rank correlation coefficient, and differences were considered statistically significant at p<0.05. Results. Our findings demonstrated a strong positive correlation between IL-1 and IL-6 (rs = 0.89; p = 0.0000), a moderate negative correlation between IL-1 and S-100 (rs = –0.298; p = 0.59), and a weak negative correlation with JADAS27 (rs = –0.278; p = 0.067). A very weak positive correlation was observed between IL-1 and TNF-α (rs = 0.15; p = 0.34) and between IL-1 and ferritin (rs = 0.18; p = 0.24). Conclusion. It has been demonstrated that systemic-onset juvenile idiopathic arthritis (sJIA) is characterized by a distinct immunological profile dominated by elevated levels of proinflammatory cytokines, including IL-1, IL-6, and IL-18, which contribute to the development of systemic clinical manifestations and disease severity. A significant positive correlation between IL-18 and ferritin levels (rs = 0.46; p = 0.0019) suggests that ferritin may serve not only as an indicator of inflammation but also as an active proinflammatory mediator involved in the immunopathogenesis of sJIA.

About the Authors

List of references

Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J Rheumatol 2004;31:390–2.

Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N, et al. American College of Rheumatology Provisional Criteria for Defining Clinical Inactive Disease in Select Categories of Juvenile Idiopathic Arthritis. Arthritis Care & Research. 2015;63(7):929–936. DOI: 10.1002/acr.20497 DOI: https://doi.org/10.1002/acr.20497

Stella Amarachi Ihim, Sharafudeen Dahiru Abubakar, Zeineb Zian, 6 Takanori Sasaki, Mohammad Saffarioun, Shayan Maleknia, and Gholamreza Azizicorresponding author Front Immunol. 2022; 13: 919973. Published online 2022 Aug 11. doi: 10.3389/fimmu.2022.919973. DOI: https://doi.org/10.3389/fimmu.2022.919973

Yasin S, Fall N, Brown RA, Henderlight M, Canna SW, Girard-Guyonvarc’h C, et al. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology (Oxford). 2020;59(2):361-366. doi: 10.1093/rheumatology/kez282.

van Loo G, Bertrand MJ (May 2023). "Death by TNF: a road to inflammation". NatureReviewsImmunology. 2023 (5): 289303. doi:10.1038/s41577-022-00792-3. DOI: https://doi.org/10.1038/s41577-022-00792-3

Croft M, Siegel RM (March 2017). "Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases". Nature ReviewsRheumatology. 13 (4): 217233. doi:10.1038/nrrheum.2017.22. PMC 5486401. PMID 28275260. DOI: https://doi.org/10.1038/nrrheum.2017.22

Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:499–505. doi: 10.1136/annrheumdis-2015-203923. DOI: https://doi.org/10.1136/annrheumdis-2013-203923

Yasin S., Vastert S.J., de Jager W. et al. IL‑18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology. 2020. DOI: 10.1093/rheumatology/kez282 DOI: https://doi.org/10.1093/rheumatology/kez282

Put K., Van Gorp H., Vanden Berghe W. Tipping the balance between interleukin‑18 and interferon‑γ in autoinflammatory diseases. Rheumatology. 2015. DOI: 10.1093/rheumatology/keu508 DOI: https://doi.org/10.1093/rheumatology/keu508

Boom V., Schulert G.S., de Jesus A. et al. Evidence‑based diagnosis and treatment of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatric Rheumatology. 2015. DOI: 10.1186/s12969-015-0055-3 DOI: https://doi.org/10.1186/s12969-015-0055-3

Girard‑Guyonvarc’h C., Volteau M., Allantaz F. et al. The Role of Interleukin‑18/Interleukin‑18‑Binding Protein in Adult-Onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis. Journal of Clinical Medicine. 2022. DOI: 10.3390/jcm11020430 DOI: https://doi.org/10.3390/jcm11020430

Souma K., Nozaki T., Koga T. Serum interleukin‑18 level as a possible early diagnostic biomarker in systemic juvenile idiopathic arthritis. International Journal of Rheumatic Diseases. 2023. DOI: 10.1111/1756-185X.14534 DOI: https://doi.org/10.1111/1756-185X.14534

Canna S.W., Grom A.A., de Jesus A. It is time for IL‑18–based trials in systemic juvenile idiopathic arthritis. Pediatric Rheumatology. 2023. DOI: 10.1186/s12969-023-00867-y DOI: https://doi.org/10.1186/s12969-023-00867-y

De Matteis A., Melki I., Hot A. Systemic juvenile idiopathic arthritis and adult-onset Still’s disease: a comprehensive review. Annals of the Rheumatic Diseases. 2024. DOI: 10.1136/ard-2024-266575

Brunner HI, Ruperto N, Tzaribachev N, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO). Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Annals of the Rheumatic Diseases. 2018;77(1):21–29. DOI: 10.1136/annrheumdis-2017-211008 DOI: https://doi.org/10.1136/annrheumdis-2016-210456

Bağlan E, et al. Retrospective evaluation of patients… Akt Rheumatol. 2022;47:152–157. DOI: 10.1055/a-1450-1436 DOI: https://doi.org/10.1055/a-1450-1436

How to Cite

Akhmedova Д., Kasimova И., & Ibragimov А. (2025). FEATURES OF THE IMMUNOLOGICAL PROFILE IN CHILDREN WITH JUVENILE ARTHRITIS OF SYSTEMIC ONSET DEPENDING ON DISEASE ACTIVITY. International Journal of Scientific Pediatrics, 4(6), 1148–1152. https://doi.org/10.56121/2181-2926-2025-4-6-1148-1152
Views: 0

Most read articles by the same author(s)